Sabatino JJ Jr, Mehta NJ, Kakar S, Zamvil SS, Cree BAC. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 5;4(4):e368.
Recently ProfG reported on a case of liver problems after daclizumab. This has happened after treatment with CRAB drugs and this is a case report of a new generic copaxone. It was reported that there the problem occurred after a few injections. So if you are using the generic version please be vigilant.
Teva has been trying to argue that their random mix of amino acids is different (even batches made by Teva are different) from others random mixes, adding to the issues of the Cop Wars.
As this is the World's leading MS drug in terms of Sales, it is not surprising that other manufacturers want a slice of the pie. No wonder there are so many court cases with the generics companies,
Just think for every few months that production of the generics and sales are held up due to legal actions, how much is made on the sales. 6 months = $2 billion so bung a few million to patent lawyers is good business.
This event has been reported in the original glatiramer acetate but occurs rarely. Since approval, over 300 cases of Copaxone-associated liver-related abnormalities were reported to the United States Food and Drug Administration (US-FDA). I am sure if there are more we will hear of them
CoI: Some of authors have received funding in numerous ways from Teva...however their patients were using competitor drug